Fluzoparib
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Fluzoparib
- Molecular weight
- 472.4
- Structure (SMILES)
- O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCn2nc(C(F)(F)F)nc2C1
- adebrelimab paclitaxel carboplatin bevacizumab fluzoparib
- adebrelimab plus fluzoparib
- arsenic trioxide tablet fuzuloparib capsules
- camrelizumab fluzoparib
- fluzoparib
- Fluzoparib
- fluzoparib and camrelizumab
- fluzoparib bevacizumab
- fluzoparib camrelizumab
- fluzoparib capsule
- Fluzoparib Capsule
- fluzoparib capsules
- Fluzoparib capsules
- Fluzoparib Capsules
- fluzoparib chidamide
- fluzoparib dalpiciclib
- fluzoparib paclitaxel
- fluzoparib with temozolomide
- fuzuloparib
- Fuzuloparib
- fuzuloparib [INN]
- Fuzuloparib [WHO-DD]
- fuzuloparib inn
- fuzuloparib who dd
- fuzuopali
And 12 more, listed on the interactive page.
- CAS registry numbers
- 1358715-18-0
- ChEMBL ID
- CHEMBL3930624
- InChIKey
- XJGXCBHXFWBOTN-UHFFFAOYSA-N
- PubChem compound IDs
- 56649297
- FDA ingredient codes (UNII)
- TWF0ML1CK8
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- fluzoparib
- Type
- Synthetic organic
- Drug name stem
- -parib
- Approval recorded by Guide to Pharmacology
- Yes
Mechanisms of action
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- poly(ADP-ribose) polymerase 1
- Gene symbol
- PARP1
- Protein identifier
- P09874
- Median affinity
- 8.05
- Affinity units
- pIC50
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Carcinoma, Renal Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000681
- Subject identifier
- D002292
- Condition
- Sarcoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000691
- Subject identifier
- D012509
- Condition
- Small Cell Lung Carcinoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000702
- Subject identifier
- D055752
- Condition
- Melanoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000756
- Subject identifier
- D008545
- Condition
- Liver Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001421
- Subject identifier
- D008107
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0002618
- Subject identifier
- D010190
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition
- Kidney Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003086
- Subject identifier
- D007674
- Condition
- Ovarian Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003893
- Subject identifier
- D010051
- Condition
- Triple Negative Breast Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005537
- Subject identifier
- D064726
- Condition
- Esophageal Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005922
- Subject identifier
- D004938
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:1000359
- Subject identifier
- D010190
- Condition
- Endometrial Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001512
- Subject identifier
- D016889
- Condition
- Sarcoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001968
- Subject identifier
- D012509
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0001056
- Subject identifier
- D013274
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0004992
- Subject identifier
- D009369
- Condition
- Breast Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0007254
- Subject identifier
- D001943
- Condition
- Ovarian Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0008170
- Subject identifier
- D010051
- Condition
- Prostatic Neoplasms, Castration-Resistant
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0008315
- Subject identifier
- D064129
- Condition
- Nasopharyngeal Carcinoma
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0015459
- Subject identifier
- D000077274
- Condition identifier
- EFO_0000174
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000681
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000691
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000756
- Condition identifier
- EFO_0001421
- Highest recorded phase
- 1
- Condition identifier
- EFO_0002618
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003060
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003086
- Highest recorded phase
- 1
- Condition identifier
- EFO_0005922
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000359
- Condition identifier
- EFO_1001968
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001056
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002158
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002974
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004992
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005070
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005097
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005105
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005140
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005192
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005494
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0006047
- Highest recorded phase
- 1
And 15 more, listed on the interactive page.
- NCT02575651
- NCT03645200
- NCT04193319
- NCT02747342
- NCT04102124
- NCT04108247
- NCT04691804
- NCT04869488
- NCT05223582
- NCT02759666
- NCT03062982
- NCT03182673
- NCT04013048
- NCT04108676
- NCT05349409
- NCT05440006
- NCT06208410
- NCT03026881
- NCT03509636
- NCT03863860
- NCT04517357
- NCT04718740
- NCT05170594
- NCT05479487
- NCT05585281
And 31 more, listed on the interactive page.
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 1
- Polar surface area
- 96.77
- Calculated partition coefficient (ALogP)
- 2.92
- Calculated partition coefficient (XLogP)
- 2.4
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 3
- Heavy atoms
- 34
- Molecular formula
- C22H16F4N6O2
- Monoisotopic mass
- 472.12708642
- Natural product
- No
- Recorded assays
- 19
- Active assays
- 8
Active assay types
- Confirmatory
- Poly(ADP-ribose) Polymerase Inhibitors
Oral bioavailability
- Median
- 35.8
- Mean
- 35.8
- Minimum
- 35.8
- Maximum
- 35.8
- Unit
- %
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Related records
Trials (96)
- A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors
- A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors
- A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer
- A Drug-drug Interaction Trial of Rifampicin Pharmacokinetics Effect on Fluzoparib
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
- A Non-interventional Registry Study of Fluzoparib in the Treatment of Ovarian Cancer
- A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer
- A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients
- A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies
- A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors
- A Phase II Clinical Study to Evaluate the Efficacy and Safety of Flazoparib Combined With Temozolomide After the Completion of Standard Concurrent Chemoradiotherapy (CCRT) in Newly Diagnosed Glioblastoma
- A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer
- A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance
- A Study of Abiraterone in Combination With SHR3162 in the Treatment of mCRPC
- A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer
- A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer
- A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC）
- A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
- A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients
- A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients
In development for (35)
- Bone sarcoma Phase 2
- Breast cancer Phase 3
- Cancer Phase 2
- Cervical cancer Phase 2
- Colorectal cancer Phase 2
- Endometrial cancer Phase 2
- Endometrial carcinoma Phase 2
- Esophageal squamous cell carcinoma Phase 2
- Ewing sarcoma Phase 2
- Exocrine pancreatic carcinoma Phase 3
- Fallopian tube cancer Phase 3
- Gastric cancer Phase 1
- Glioblastoma Phase 2
- Kidney disorder Phase 1
- Liver disorder Phase 1
- Malignant epithelial tumor of ovary Phase 2
- Malignant pancreatic neoplasm Phase 3
- Melanoma Phase 1
- Nasopharyngeal carcinoma Phase 2
- Neoplasm Phase 2